West Pharmaceutical Services (NYSE:WST) said today that it’s launching the NovaPure 3mL cartridge components with its NovaPure product line for delivery of higher-volume injectable drug-delivery systems.
The Exton, Pa.-based company also announced that its SmartDose Gen. II 10mL injector for subcutaneous drug delivery is available for commercialization as well.
West’s NovaPure portfolio currently includes stoppers and syringe plungers, but will now add the NovaPure 3mL cartridge components. The components are designed for cartridges often used in auto-injectors and other drug-delivery devices.
The SmartDose Gen. II 10mL system adds to the SmartDose portfolio for convenient home-based drug administration for patients with chronic health conditions. The Gen. II 10mL system is designed to adhere to the patient’s body to remain hands-free during the injection.
West unveiled the wearable SmartDose in November 2017 and, in February of this year, announced an agreement for the SmartDose to deliver scPharmaceuticals’ (NSDQ:SCPH) Furoscix drug designed to treat edema in heart failure patients.
“Our customers face a number of demands from increasing regulations and requirements, to evolving patient needs, to an ever-changing healthcare landscape,” SVP & chief commercial officer Karen Flynn said in prepared remarks. “Our goal is to simplify their journey and work by their side to support them with products, services and solutions. We aim to speed their development and to help ensure a continuous supply to the market of important therapies which drive better patient outcomes. The launch of our NovaPure 3mL cartridge components line and the enhancements to our SmartDose platform are the first of many upcoming product launches and updates we’ll be announcing in the coming months to address specific issues we know our customers are facing as they work to bring innovative, new injectable medicines to market.”
Shares of WST were down -0.5% at $139.26 per share in midday trading today.
